The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pathological images machine learning and prediction of long-term efficacy for immunotherapy in small cell lung cancer.
 
Yuki Sato
Honoraria - AstraZeneca; Bristol-Myers Squibb Co Ltd; Chugai Pharma; Kyowa Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Ryota Shibaki
No Relationships to Disclose
 
Daichi Fujimoto
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Co Ltd; Chugai Pharma; Kyowa Kirin; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca Japan; Chugai Pharma
Research Funding - AstraZeneca Japan; Boehringer Ingelheim (Inst); Chugai Pharma (Inst)
 
Tsukasa Nozawa
No Relationships to Disclose
 
Satoshi Hara
No Relationships to Disclose
 
Junji Uchida
No Relationships to Disclose
 
Eisaku Miyauchi
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Meyers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Kyowa Kirin Co Ltd; Lilly; Lilly Japan; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo KK; Lilly; Merck
Research Funding - Chugai Pharma (Inst); Lilly (Inst)
 
Ryota Hiraoka
No Relationships to Disclose
 
Haruko Daga
Honoraria - AstraZeneca; Chugai/Roche
Research Funding - AstraZeneca (Inst); Chugai/Roche (Inst); Lilly (Inst)
 
Takeshi Masuda
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Kirin International; Kyowa Kirin International; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - MSD K.K
 
Satoshi Tanaka
No Relationships to Disclose
 
Satoshi Ikeda
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca
Research Funding - AstraZeneca; Chugai Pharma (Inst)
 
Go Saito
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Hidekazu Suzuki
Honoraria - Boehringer Ingelheim; Chugai Pharma; Lilly O.; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Shinya Sakata
Honoraria - AstraZeneca; Chugai Pharma; Takeda
 
Yoshihiko Sakata
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Chugai Pharma; Lilly O.; MSD; Taiho Pharmaceutical; Takeda
 
Takashi Kijima
Honoraria - Chugai Pharma
 
Nobuyuki Yamamoto
Honoraria - Amgen; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck; MSD; Novartis; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Takeda; Thermo Fisher Scientific
Research Funding - A2 Healthcare; Abbvie (Inst); Amgen; Amgen (Inst); Asahi Kasei (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Corporation; IQvia; Janssen (Inst); Lilly (Inst); Mebix; MSD (Inst); Novartis (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Yasuhiro Koh
Honoraria - Amgen; Chugai Pharma; Guardant Health; Takeda; Tosoh Corporation
Consulting or Advisory Role - Tosoh Corporation
Research Funding - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Takeda (Inst); Tosoh Corporation; Zeon Corporation
 
Hiroaki Akamatsu
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Chugai Pharma; Lilly; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Janssen; Sandoz
Research Funding - Amgen (Inst); Chugai Pharma (Inst)